Pathophysiology roles and translational opportunities of miRNAs in pancreatic cancer

Sayra Dilmac, Bulent Ozpolat

Research output: Chapter in Book/Report/Conference proceedingChapter


Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest human cancers, with 6months of median survival. PDAC is the fourth-leading cause of cancer mortality. Intrinsic resistance to chemotherapeutics and a lack of effective therapies are the major factors contributing to this poor prognosis. Due to nonspecific symptoms and the unavailability of early diagnostic tools, the majority of patients are diagnosed at an advanced stage, for which the 5-year survival rate is 3%. PDAC is associated with genetic alterations, including KRAS mutations (detected in ~90% of cases) and inactivation of tumor suppressors, such as TP53 (~70%), SMAD4 (20%-50%), and CDKN2A (50%-90%), as well as a unique tumor microenvironment with excessive stroma, promoting tumor growth and contributing to treatment failures.

Original languageEnglish (US)
Title of host publicationMicroRNA in Human Malignancies
Number of pages9
ISBN (Electronic)9780128222874
ISBN (Print)9780128232743
StatePublished - Jan 1 2022


  • miRNA
  • Pancreatic cancer
  • PanIN
  • PDAC

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Pathophysiology roles and translational opportunities of miRNAs in pancreatic cancer'. Together they form a unique fingerprint.

Cite this